Sentry Investment Management LLC lessened its stake in shares of Allergan plc (NYSE:AGN) by 2.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,449 shares of the company’s stock after selling 640 shares during the quarter. Sentry Investment Management LLC’s holdings in Allergan were worth $4,086,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in AGN. Edgewood Management LLC raised its position in Allergan by 2.6% in the second quarter. Edgewood Management LLC now owns 5,728,391 shares of the company’s stock worth $955,037,000 after acquiring an additional 144,282 shares in the last quarter. Janus Henderson Group PLC raised its position in Allergan by 16.3% in the second quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock worth $796,712,000 after acquiring an additional 668,343 shares in the last quarter. Northern Trust Corp raised its position in Allergan by 1.7% in the second quarter. Northern Trust Corp now owns 4,163,556 shares of the company’s stock worth $694,149,000 after acquiring an additional 69,651 shares in the last quarter. Bank of New York Mellon Corp raised its position in Allergan by 2.9% in the second quarter. Bank of New York Mellon Corp now owns 3,545,557 shares of the company’s stock worth $591,116,000 after acquiring an additional 99,490 shares in the last quarter. Finally, Parnassus Investments CA raised its position in Allergan by 3.1% in the second quarter. Parnassus Investments CA now owns 1,844,804 shares of the company’s stock worth $307,566,000 after acquiring an additional 55,029 shares in the last quarter. Institutional investors and hedge funds own 77.55% of the company’s stock.
AGN opened at $165.52 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.78 and a debt-to-equity ratio of 0.32. The firm has a market cap of $57.21 billion, a P/E ratio of 10.12, a P/E/G ratio of 1.34 and a beta of 1.31. Allergan plc has a 52 week low of $142.81 and a 52 week high of $197.00.
Allergan (NYSE:AGN) last posted its quarterly earnings data on Tuesday, October 30th. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $4.04 by $0.21. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.89 billion. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $4.15 earnings per share. Equities analysts predict that Allergan plc will post 16.42 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Tuesday, November 13th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.74%. The ex-dividend date is Friday, November 9th. Allergan’s payout ratio is currently 17.61%.
In other Allergan news, Director Joseph H. Boccuzi purchased 900 shares of the firm’s stock in a transaction on Thursday, August 30th. The shares were purchased at an average cost of $190.59 per share, with a total value of $171,531.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christopher J. Coughlin purchased 10,000 shares of the firm’s stock in a transaction on Thursday, September 6th. The stock was acquired at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. 0.36% of the stock is owned by company insiders.
A number of research analysts have recently weighed in on AGN shares. Guggenheim started coverage on Allergan in a research report on Monday, October 8th. They issued a “buy” rating for the company. ValuEngine upgraded Allergan from a “strong sell” rating to a “sell” rating in a research report on Friday, September 21st. Raymond James dropped their price target on Allergan from $232.00 to $198.00 and set a “buy” rating for the company in a research report on Wednesday, October 31st. Credit Suisse Group set a $213.00 price target on Allergan and gave the company a “buy” rating in a research report on Friday, July 13th. Finally, Zacks Investment Research upgraded Allergan from a “hold” rating to a “buy” rating and set a $193.00 price target for the company in a research report on Tuesday, July 24th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and eighteen have issued a buy rating to the stock. Allergan presently has a consensus rating of “Buy” and an average target price of $210.18.
COPYRIGHT VIOLATION WARNING: “Sentry Investment Management LLC Has $4.09 Million Stake in Allergan plc (AGN)” was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/11/10/sentry-investment-management-llc-has-4-09-million-stake-in-allergan-plc-agn.html.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Read More: Penny Stocks, What You Need To Know
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.